Drug curbs albuminuria, cholesterol in type 2 diabetes, nephropathy

06/5/2013 | Medscape (free registration)

A study presented at the European Renal Association-European Dialysis and Transplant Association meeting found patients with type 2 diabetes and nephropathy who received atrasentan attained improvements in albuminuria and bad cholesterol and triglyceride levels at 12 weeks compared with those who took a placebo. However, the findings merit further and longer-term assessment to see whether the drug would be beneficial, a researcher said.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Chief Medical Officer
Nashville, TN
Commercial Health Insurance Strategist__Job #52-14
American Academy of Family Physicians
Leawood, KS
Manager of Payer Relations
Pharmacy Quality Solutions, Inc.
Raleigh/Durham, NC